Document is current
Any future updates will be listed below
-
Authors
Zarkali, Angeliki https://orcid.org/0000-0003-2808-072X
Thomas, George E. C. https://orcid.org/0000-0001-6107-0326
Zetterberg, Henrik
Weil, Rimona S. https://orcid.org/0000-0002-5092-6325
-
Funding
Funding for this research was provided by:
Wellcome Trust (225263/Z/22/Z, 225263/Z/22/Z)
Alzheimer's Research UK (2021B-001)
- License Information
-
More Information
Article History
Received: 26 July 2023
Accepted: 19 June 2024
First Online: 5 July 2024
Competing interests
: R.W. has received speaking and writing honoraria respectively from GE Healthcare and Britannia, and consultancy fees from Therakind, and is local PI for an EIP neflamapimod trial. H.Z. has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). The remaining authors report no competing interests.
